17
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T16557 | PNU-159682 | Topoisomerase | |
PNU-159682 is a highly effective metabolite of the anthracycline nemorubicin. PNU-159682 has outstanding cytotoxicity. PNU-159682 is an effective ADCs cytotoxin. | |||
T76692 | Mosunetuzumab | BTCT-4465A | Others |
Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to stu... | |||
T76794 | Ulocuplumab | BMS 936564,MDX 1338 | Apoptosis , CXCR |
Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.Ulocplu... | |||
T28694 | SB-743921 free base | SB743921,SB-921,SB921,SB-743921,GSK-743921,GSK-921 | |
SB-743921, a kinesin spindle protein (KSP) inhibitor, is used potentially for the treatment of non-Hodgkin's lymphoma (NHL). | |||
T76768 | Pinatuzumab | ||
Pinatuzumab, a CD22 monoclonal antibody, specifically targets the CD22 cell-surface antigen and is utilized in the synthesis of antibody-drug conjugates (ADCs) for researching a range of diseases, including non-Hodgkin l... | |||
T77070 | Loncastuximab | ||
Loncastuximab (RB4v1.2), an anti-CD19 monoclonal antibody, exhibits antitumor properties and holds potential for treating non-Hodgkin's lymphoma (NHL), specifically diffuse large B-cell lymphoma (DLBCL) [1] [2]. | |||
T68980 | MRK003 | ||
MRK003 is a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. MRK003 treatment induced caspase-dependent apoptosis and inhibited proliferation of MM a... | |||
T78331 | Epcoritamab | GEN3013 | |
Epcoritamab (GEN3013) is a bispecific IgG1 antibody that redirects T-cells toward CD3×CD20-positive tumor cells, inducing potent T-cell-mediated cytotoxicity against B-cell non-Hodgkin lymphoma (NHL) cell lines [1]. | |||
T63942 | WNY1613 | ||
WNY1613 is a potent and selective PI3Kδ inhibitor with a piperazinone-containing purine scaffold.WNY1613 has anti-NHL effects in vitro and in vivo.WNY1613 inhibits phosphorylation of the downstream component of PI3K in N... | |||
T77183 | Ripertamab | ||
Ripertamab (SCT400), a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody (mAb), has applications in the research of hematological malignancies, particularly non-Hodgkin’s lymphoma (NHL) [1]. | |||
T82576 | Detumomab | SPECIFID | |
Detumomab is a mouse monoclonal antibody designed to target human B-cell lymphoma, and is utilized in research pertaining to various cancers, including non-Hodgkin's lymphoma (NHL). | |||
T76765 | Veltuzumab | ||
Veltuzumab (IMMU-106), a humanized anti-CD20 monoclonal antibody, exhibits a low EC50 value ranging from 0.08 to 0.09 μg/mL in the Daudi cell line. It is used in cancer research, specifically for non-Hodgkin lymphoma (NH... | |||
T82078 | Iladatuzumab | MCDS0593A | |
Iladatuzumab (MCDS0593A), a humanized IgG1 monoclonal antibody targeting CD79B, serves as a precursor for the synthesis of antibody-drug conjugates (ADCs), such as Iladatuzumab vedotin (DCDS0780A), with potential applica... | |||
T77033 | Imvotamab | ||
Imvotamab (IGM-2323), a CD20xCD3 bispecific IGM antibody featuring a dual-action mechanism, promotes physiological T cell activation to avoid both over-stimulation and immune function down-regulation. This compound is un... | |||
T76920 | Bectumomab | ||
Bectumomab (IMMU-LL 2), a humanized IgG2a monoclonal antibody (mAb) against human CD22 (antigen), serves as an anti-lymphoma agent. It is utilized in imaging procedures when combined with technetium 99 (Tc99m LL2 Fab), a... | |||
T71227 | LGB-321 HCl | ||
LGB-321 is a potent and selective ATP-competitive small molecule inhibitor of PIM kinases (Pan-PIM kinase inhibitor). LGB321 is unique relative to previously described PIM inhibitors, in that it is active in PIM2 depende... | |||
T76805 | Epratuzumab | ||
Epratuzumab (Antibody hLL 2), an anti-CD22 IgG1 monoclonal antibody, serves as both a tumor-imaging and immunomodulatory agent. It induces CD22 phosphorylation and has been employed in researching Non-Hodgkin’s Lymphomas... |